StreetInsider.com News Articles

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today provided a business update.

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and

Adagio Medical Provides Business Updates

Mon, 19 Aug 2024 16:01:00 -0400

Recent Business Highlights:

Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets
Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal
Obtained the U.S. Food and Drug Administration (“FDA”) approval for the FULCRUM-VT Pivotal IDE study
Closed business combination and